DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation1 article · 1 moderate

EU GMP

Every DSRV article whose Regulatory Snapshot cites EU GMP: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under EU GMP?
1 DSRV article cite EU GMP. Enforcement cases behind them: Provisional political agreement of EU lawmakers, May 7, 2026 (the Omnibus deal), extending the high-risk AI compliance deadline of the EU AI Act (Regulation (EU) 2024/1689) from August 2, 2026 to December 2, 2027 for standalone Annex III systems; formal adoption by the Council and Parliament was still pending as of May 2026. Inspection exposure across them: 1 moderate.
What does DSRV recommend for EU GMP?
From the newest article (EU AI Act Delays High-Risk Deadline to December 2027): The extension moves one arrival date, not the roadmap; firms that use the sixteen months to finish AI use-case inventories, ownership assignment, and documented risk assessments arrive defensible, while firms that deprioritize will face the same gap in late 2027 with far less room to close it. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readModerate exposurecited as a tag

    EU AI Act Delays High-Risk Deadline to December 2027

    EU lawmakers reached a provisional deal on May 7 to push the high-risk AI compliance deadline from August 2, 2026 to December 2, 2027. For pharma quality AI programs, the window is larger. The destination has not moved.

    Case
    Provisional political agreement of EU lawmakers, May 7, 2026 (the Omnibus deal), extending the high-risk AI compliance deadline of the EU AI Act (Regulation (EU) 2024/1689) from August 2, 2026 to December 2, 2027 for standalone Annex III systems; formal adoption by the Council and Parliament was still pending as of May 2026.
    DSRV take
    The extension moves one arrival date, not the roadmap; firms that use the sixteen months to finish AI use-case inventories, ownership assignment, and documented risk assessments arrive defensible, while firms that deprioritize will face the same gap in late 2027 with far less room to close it.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under EU GMP. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about EU GMP

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.